Abstract:Alzheimer's disease (AD), the most common disabling impairment in older adults, takes an unacceptable toll on patients and families. With the growing number of people living to older ages, it is projected to afflict more than 100 million people around the world by 2050. While there is an urgent need, it takes too many cognitively normal (CN) individuals and too many years to evaluate presymptomatic AD treatments using traditional clinical endpoints. We and our colleagues have been using imaging techniques to detect the brain changes associated with the predisposition to AD in CN individuals with 2, 1 and 0 copies of the apolipoprotein E (APOE) e4 allele, the major late-onset AD susceptibility gene, and in CN presenilin 1 (PSEN1) mutation carriers and non-carriers from the world’s largest autosomal dominant early-onset AD kindred in Antioquia, Colombia; we developed several image-analysis techniques and a composite cognitive measure with improved power; and we estimated the sample sizes needed when using these endpoints. We recently proposed the Alzheimer’s Prevention Initiative (API) to help in the effort to launch an era in AD prevention research. The API will include preclinical AD treatment/biomarker development trials in individuals at increased genetic risk for early-onset and late-onset AD, an extremely large Colombian early-onset AD Prevention Registry; and an extremely large North American Alzheimer’s Prevention Registry to support several preclinical AD trials. The API’s first trial will test the anti-amyloid immunization therapy crenezumab in CN PSEN1 mutation carriers using the best established brain imaging and cerebrospinal fluid measurements and our composite cognitive measure as the primary clinical endpoint. It is intended to test an anti-amyloid agent in the preclinical treatment of AD, help determine the extent to which a treatment’s biomarker effects predict a clinical outcome, provide a better test of the amyloid hypothesis, and provide raw data and biological samples to the research community. With support from the U.S. National Institutes of Health, philanthropic funds from the Banner Alzheimer’s Institute, and Genentech, it is also intended to help provide a new paradigm for research collaboration in clinical trials. In this presentation, we will briefly introduce the crucial role of flourodeoxyglucose positron emission tomography (PET), amyloid PET, structural and functional MRI in the preclinical detection, tracking, and treatment of AD. We will present the novel image processing methods we have developed to help in this endeavor, as well as their implementation in the API’s preclinical treatment/biomarker development programs.

Brain Imaging Biomarkers for the Alzheimer’s Prevention Initiative

Alzheimer's Prevention Initiative: a Plan to Accelerate the Evaluation of Presymptomatic Treatments.

P3-287: Composite Cognitive Endpoints with Improved Power to Detect Presymptomatic Alzheimer's Disease Treatment Effects: Findings in the Colombian Kindred with the E280A Presenilin 1 Mutation and the Alzheimer's Prevention Initiative

Composite cognitive endpoints with improved power to detect presymptomatic Alzheimer's disease treatment effects in APOE4 carriers: Findings from the Alzheimer's prevention initiative

SAMPLE SIZES FOR 24-MONTH ALZHEIMER’S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS

[IC‐P‐041]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS

[O5–01–04]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS

P4‐209: A PUBLIC RESOURCE OF BASELINE DATA FROM THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE COLOMBIA TRIAL

RELATIONSHIPS BETWEEN BASELINE BRAIN IMAGING BIOMARKER MEASUREMENTS AND AGE IN THE API AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE COLOMBIA TRIAL

TRIAL DESIGN, DATA SHARING RISK MITIGATION, AND BASELINE CLINICAL AND COGNITIVE DATA FROM THE API AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE COLOMBIA TRIAL

Positron Emission Tomography and Magnetic Resonance Imaging in the Study of Cognitively Normal Persons at Differential Genetic Risk for Alzheimer’s Dementia

O1‐01‐04: Age‐associated Trajectories of Biomarkers in Early‐onset Alzheimer's Disease, for the Alzheimer's Prevention Initiative

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact

Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies

Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease

Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease.

Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques

Preserving cognitive function in patients with Alzheimer's disease: The Alzheimer's disease neuroprotection research initiative (ADNRI)

Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI)

A public resource of baseline data from the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial

O2-03-01: Validation of the Alzheimer's Prevention Initiative Composite Cognitive Test Score